Insmed Incorporated (NASDAQ:INSM) Shares Purchased by Federated Hermes Inc.

Federated Hermes Inc. increased its stake in shares of Insmed Incorporated (NASDAQ:INSM) by 448.7% in the 4th quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 235,836 shares of the biopharmaceutical company’s stock after purchasing an additional 192,853 shares during the period. Federated Hermes Inc. owned 0.13% of Insmed worth $16,282,000 as of its most recent filing with the Securities & Exchange Commission.

Several other hedge funds have also recently modified their holdings of the stock. Captrust Financial Advisors raised its holdings in Insmed by 40.9% in the 3rd quarter. Captrust Financial Advisors now owns 6,280 shares of the biopharmaceutical company’s stock valued at $458,000 after acquiring an additional 1,824 shares during the last quarter. Wellington Management Group LLP raised its holdings in Insmed by 2.6% in the 3rd quarter. Wellington Management Group LLP now owns 962,459 shares of the biopharmaceutical company’s stock valued at $70,260,000 after acquiring an additional 24,025 shares during the last quarter. Orion Portfolio Solutions LLC raised its holdings in Insmed by 48.5% in the 3rd quarter. Orion Portfolio Solutions LLC now owns 28,087 shares of the biopharmaceutical company’s stock valued at $2,050,000 after acquiring an additional 9,170 shares during the last quarter. MML Investors Services LLC raised its holdings in Insmed by 36.2% in the 3rd quarter. MML Investors Services LLC now owns 22,201 shares of the biopharmaceutical company’s stock valued at $1,621,000 after acquiring an additional 5,897 shares during the last quarter. Finally, M&T Bank Corp acquired a new stake in Insmed in the 3rd quarter valued at about $218,000.

Insider Transactions at Insmed

In other news, insider Orlov S. Nicole Schaeffer sold 91,140 shares of Insmed stock in a transaction on Thursday, January 30th. The shares were sold at an average price of $80.00, for a total transaction of $7,291,200.00. Following the completion of the sale, the insider now directly owns 97,083 shares of the company’s stock, valued at approximately $7,766,640. The trade was a 48.42 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, insider Martina M.D. Flammer sold 6,172 shares of Insmed stock in a transaction on Friday, January 10th. The stock was sold at an average price of $63.64, for a total transaction of $392,786.08. Following the sale, the insider now owns 101,549 shares in the company, valued at $6,462,578.36. This represents a 5.73 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last three months, insiders sold 514,731 shares of company stock valued at $40,530,912. Insiders own 4.60% of the company’s stock.

Insmed Stock Performance

Shares of INSM stock opened at $67.55 on Thursday. The company has a quick ratio of 5.99, a current ratio of 6.37 and a debt-to-equity ratio of 2.03. Insmed Incorporated has a 52 week low of $21.92 and a 52 week high of $84.91. The stock has a market capitalization of $12.23 billion, a PE ratio of -12.08 and a beta of 1.07. The firm has a 50 day moving average of $76.71 and a two-hundred day moving average of $73.73.

Insmed (NASDAQ:INSM) last released its quarterly earnings data on Thursday, February 20th. The biopharmaceutical company reported ($1.32) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.17) by ($0.15). The firm had revenue of $104.44 million for the quarter, compared to analysts’ expectations of $102.31 million. Insmed had a negative return on equity of 4,773.73% and a negative net margin of 251.24%. On average, research analysts predict that Insmed Incorporated will post -4.56 EPS for the current fiscal year.

Analyst Ratings Changes

A number of analysts have commented on the stock. UBS Group increased their price objective on shares of Insmed from $105.00 to $110.00 and gave the company a “buy” rating in a report on Thursday, March 6th. HC Wainwright restated a “buy” rating and set a $90.00 price target on shares of Insmed in a report on Friday, February 21st. Royal Bank of Canada restated an “outperform” rating and set a $100.00 price target on shares of Insmed in a report on Wednesday, March 19th. Stifel Nicolaus cut their price target on shares of Insmed from $97.00 to $96.00 and set a “buy” rating for the company in a report on Friday, February 21st. Finally, Morgan Stanley raised their price target on shares of Insmed from $85.00 to $90.00 and gave the stock an “overweight” rating in a report on Thursday, February 6th. One investment analyst has rated the stock with a sell rating and sixteen have assigned a buy rating to the company. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus target price of $94.00.

Insmed Profile

Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed’s first commercial product is ARIKAYCE® (amikacin liposome inhalation suspension), which is approved in the United States for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options.